Marjon V. Verschueren
Utrecht, UT, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Real World Effectiveness of Durvalumab in Stage III Unresectable Non-small Cell Lung Cancer: What is the Role of PD-L1 Expression?
Journal: Clinical lung cancer
Published: March 03, 2025
A Bayesian Approach to Compare Accumulating Survival Data From Clinical Practice With RCT Data: A Case Study in Non-Small Cell Lung Cancer Patients.
Journal: CPT: pharmacometrics & systems pharmacology
Published: December 16, 2024
Comparative Effectiveness of Nivolumab and Ipilimumab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in PD-L1 Negative Metastatic Non-Small Cell Lung Cancer Patients.
Journal: Clinical lung cancer
Published: September 17, 2024
Pembrolizumab Plus Chemotherapy Per PD-L1 Stratum In Patients With Metastatic Non-Small Cell Lung Cancer: Real-World Effectiveness Versus Trial Efficacy.
Journal: Clinical lung cancer
Published: September 29, 2023
Durvalumab after chemoradiotherapy in patients with stage III non-small-cell lung cancer: real-world outcomes versus clinical trial results.
Journal: Immunotherapy
Published: June 09, 2023
Exploring the impact of patient-specific clinical features on osimertinib effectiveness in a real-world cohort of patients with EGFR mutated non-small cell lung cancer.
Journal: International journal of cancer
Published: December 29, 2022
Critical appraisal of evidence for anti-Xa monitoring and dosing of low-molecular-weight heparin in renal insufficiency.
Journal: Expert review of clinical pharmacology
Published: October 03, 2022
Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands.
Journal: Scientific reports
Published: November 23, 2020
Showing 1-8 of 8
Last Updated: 09/26/2026